Recent media reports have highlighted Japan’s concerns over a potential Chinese restriction on exports of antibiotic active pharmaceutical ingredients (APIs). This anxiety stems from China’s dominant role in the global antibiotic supply chain—approximately 70% of the world’s antibiotic APIs are produced in China. As a country heavily reliant on imported pharmaceutical raw materials, Japan’s domestic drug manufacturers depend significantly on Chinese intermediates and APIs. Any Chinese export curbs—driven by environmental regulations, industrial policy shifts, or national security considerations—could disrupt Japan’s and even the global pharmaceutical supply chain. However, there is currently no official evidence that China plans to impose such restrictions. Experts suggest that these concerns reflect broader vulnerabilities arising from the over-concentration of critical medical supply chains and are prompting countries like Japan to accelerate efforts toward supply diversification and domestic production capacity rebuilding. While a significant Chinese export restriction on antibiotics remains unlikely in the short term, global attention to the security of essential medical supplies continues to grow.
近期，有媒体报道称日本担忧中国可能限制抗生素原料药的出口。这一担忧源于中国在全球抗生素产业链中的关键地位——全球约70%的抗生素原料药产自中国。日本作为高度依赖进口医药原料的国家，其国内制药企业大量使用来自中国的中间体和活性药物成分（API）。若中国出于环保、产业政策调整或出口管制等原因收紧相关产品出口，将可能对日本乃至全球的药品供应链造成冲击。不过，目前尚无官方证据表明中国计划实施此类限制。专家指出，此类担忧更多反映了全球医药供应链过度集中所带来的潜在风险，也促使日本等国加快推动供应链多元化和本土生产能力的重建。总体而言，尽管短期内中国大幅限制抗生素出口的可能性较低，但各国对关键医疗物资供应安全的关注正在持续上升。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/16379.html